Advertisement

ADVERTISEMENT

Stephanie Holland

Conference Coverage
Randomized Study Demonstrates Efficay of [177Lu] Lu-DOTA-TATE in First-Line Setting for Advanced Gastroenteropancreatic Neuroendocrine Tumors
01/19/2024
According to primary analysis results from the phase 3 NETTER-2 study, first-line [177Lu] Lu-DOTA-TATE significantly prolonged PFS and demonstrated a clinically meaningful ORR among patients with newly diagnosed, advanced grade 2 and 3...
According to primary analysis results from the phase 3 NETTER-2 study, first-line [177Lu] Lu-DOTA-TATE significantly prolonged PFS and demonstrated a clinically meaningful ORR among patients with newly diagnosed, advanced grade 2 and 3...
According to primary analysis...
01/19/2024
Oncology
News
Perioperative Pembrolizumab Demonstrates Long-Term Safety, Efficacy Among Patients With Late-Stage, Resectable Cutaneous Melanoma
09/01/2023
According to 5-year follow-up results from a phase 1b study, pembrolizumab is safe and effective in both the neoadjuvant and adjuvant settings among patients with resectable, stage III to IV cutaneous melanoma who have achieved a pathological...
According to 5-year follow-up results from a phase 1b study, pembrolizumab is safe and effective in both the neoadjuvant and adjuvant settings among patients with resectable, stage III to IV cutaneous melanoma who have achieved a pathological...
According to 5-year follow-up...
09/01/2023
Oncology
News
Adjuvant Osimertinib Significantly Improved Overall Survival Among Patients With EGFR-Mutated NSCLC
07/10/2023
According to final analysis results from the phase 3 ADAURA trial, adjuvant osimertinib significantly improved overall survival among patients with completely resected EGFR-mutated, stage 1B-2A NSCLC.
According to final analysis results from the phase 3 ADAURA trial, adjuvant osimertinib significantly improved overall survival among patients with completely resected EGFR-mutated, stage 1B-2A NSCLC.
According to final analysis...
07/10/2023
Oncology
News
First-Line Durvalumab Improved Overall Survival Among Select Patients With Advanced Non-Small Cell Lung Cancer and ECOG Performance Status 2
02/14/2024
According to results from the SAKK 19/17 trial, first-line durvalumab caused a high number of early fatal events among patients with advanced, PD-L1-positive NSCLC and an ECOG performance status of 2 however, when patients with grade ≥3...
According to results from the SAKK 19/17 trial, first-line durvalumab caused a high number of early fatal events among patients with advanced, PD-L1-positive NSCLC and an ECOG performance status of 2 however, when patients with grade ≥3...
According to results from the...
02/14/2024
Oncology
News
Fulvestrant Did Not Significantly Improve Response Rate Compared to Anastrozole in ER-Positive, HER2-Negative Early Breast Cancer
02/09/2024
Results from a phase 3 trial found fulvestrant with or without anastrozole did not significantly improve 6-month endocrine-sensitive disease rate compared to anastrozole alone among postmenopausal patients with ER-positive, HER2-negative,...
Results from a phase 3 trial found fulvestrant with or without anastrozole did not significantly improve 6-month endocrine-sensitive disease rate compared to anastrozole alone among postmenopausal patients with ER-positive, HER2-negative,...
Results from a phase 3 trial...
02/09/2024
Oncology
FDA Approval
FDA Approves Osimertinib Plus Platinum-Based Chemotherapy For Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer
02/21/2024
Based on results from the phase 3 FLAURA 2 trial, the FDA has approved osimertinib plus platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 19 deletions or exon 21 L858R...
Based on results from the phase 3 FLAURA 2 trial, the FDA has approved osimertinib plus platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 19 deletions or exon 21 L858R...
Based on results from the phase...
02/21/2024
Oncology
News
Capivasertib Plus Fulvestrant Approved for Patients With HR-Positive, HER2-Negative Breast Cancer
11/20/2023
Based on results from the phase 2 CAPItello-291 study, the FDA has approved capivasertib plus fulvestrant for patients with previously treated HR-positive, HER2-negative, locally advanced or metastatic breast cancer harboring one or more...
Based on results from the phase 2 CAPItello-291 study, the FDA has approved capivasertib plus fulvestrant for patients with previously treated HR-positive, HER2-negative, locally advanced or metastatic breast cancer harboring one or more...
Based on results from the phase...
11/20/2023
Oncology
News
Lazertinib as Another First-Line Option for Patients With EGFR-Mutated, Advanced NSCLC
08/02/2023
According to results from the phase 3 LASER301 trial, lazertinib significantly improved efficacy compared to gefitinib among patients with treatment-naïve EGFR-mutated advanced NSCLC, with a manageable safety profile.
According to results from the phase 3 LASER301 trial, lazertinib significantly improved efficacy compared to gefitinib among patients with treatment-naïve EGFR-mutated advanced NSCLC, with a manageable safety profile.
According to results from the...
08/02/2023
Oncology
News
Selinexor Maintenance Therapy Improved PFS Among Patients With TP53 Wild-Type Advanced or Recurrent Endometrial Cancer
10/12/2023
Results from an exploratory analysis of the ENGOT-EN5/GOG-3055/SIENDO study identified that selinexor maintenance therapy improved PFS among patients with TP53 wild-type advanced or recurrent endometrial cancer.
Results from an exploratory analysis of the ENGOT-EN5/GOG-3055/SIENDO study identified that selinexor maintenance therapy improved PFS among patients with TP53 wild-type advanced or recurrent endometrial cancer.
Results from an exploratory...
10/12/2023
Oncology
Conference Coverage
Cabozantinib Plus Atezolizumab Significantly Prolonged PFS in Metastatic Castration-Resistant Prostate Cancer
01/25/2024
Results from the ongoing phase 3 CONTACT-2 trial demonstrated that cabozantinib plus atezolizumab significantly improved rPFS compared to abiraterone plus prednisone or enzalutamide among patients with metastatic castration-resistant prostate...
Results from the ongoing phase 3 CONTACT-2 trial demonstrated that cabozantinib plus atezolizumab significantly improved rPFS compared to abiraterone plus prednisone or enzalutamide among patients with metastatic castration-resistant prostate...
Results from the ongoing phase 3...
01/25/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

December 4 ⁠–⁠ December 5
Great Debates & Updates in Diabetic Foot
December 6 ⁠–⁠ December 7
December 9 ⁠–⁠ December 11
AIBD logo
December 9 ⁠–⁠ December 11
Psych Congress Primary Care Online Series
December 12 ⁠–⁠ December 13
December 14 ⁠–⁠ December 15
February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use